Total IP	114
Total IP Rank #	11,482
IP Activity Score	2.9/5.0    117
IP Activity Rank #	5,877
Stock Symbol	PRLD (nasdaq)
ISIN	US74065P1012
Market Cap.	52.50M  (USD)
Dominant Nice Class	Scientific, technological and in...

Patents Trademarks 47 2 13 2 48 2 0
Last Patent	2025 - Brm targeting compounds and asso...
First Patent	2017 - Selective inhibitors of protein ...
Last Trademark	2019 - PRELUDE THERAPEUTICS
First Trademark	2019 - PRELUDE THERAPEUTICS

Industry (Nice Classification)

Latest Inventions, Goods, Services 2024 Invention Brm targeting compounds and associated methods of use. The disclosure is directed to compounds o... Invention Mutant pi3k-alpha inhibitors and their use as pharmaceuticals. The disclosure is directed to com... Invention Mutant pi3k-alpha inhibitors and their use as pharmaceuticals. The disclosure is directed to comp... Invention Treatment of recurrent high-grade glioma or uveal melanoma (um) using a brain-penetrant protein a... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to compounds of Form... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to compounds of Formu... 2023 Invention Brm targeting compounds and associated methods of use. The present disclosure provides bifunction... Invention Treatment of cancers using combinations of smarca2 degraders and kras targeting therapies. Method... Invention Brm targeting compounds and associated methods of use. The disclosure is directed to compounds of... Invention Kat6 targeting compounds. The present disclosure provides bifunctional compounds comprising a ta... Invention Kat6 targeting compounds with ubiquitin ligase binding moiety. The present disclosure provides bi... Invention Processes for making prmt5 inhibitors. The disclosure provides processes for preparing the compou... Invention 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 pr... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to, in part, to CDK ... Invention Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals. The disclosure is directed t... 2022 Invention Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (prm... Invention Crystalline forms of a cdk9 inhibitor and uses thereof. The present disclosure provides novel cr... Invention Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof. Th... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to, in part, to CDK i... Invention Brm targeting compounds and associated methods of use. The present disclosure provides bifunctio... Invention Polymorphic compounds and uses thereof. The present invention provides freebase and salt forms us... 2021 Invention Processes for making prmt5 inhibitors. The disclosure provides processes for preparing the compo... Invention Heterocycle cdk inhibitors and their use thereof. The disclosure is directed to, in part, to het... Invention Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein. The disc... Invention Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein. The ... 2020 Invention Selective inhibitors of protein arginine methyltransferase 5 (prmt5). The disclosure is directed... 2019 G/S Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, and... G/S Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, an...